ClinicalTrials.Veeva

Menu
S

Segal Trials | Behavioral Clinical Research, Inc.

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SEP-363856
MK-8189
KarXT
Buprenorphine
Psilocybin
MK-8189-008

Parent organization

This site is a part of Segal Trials

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 7 total trials

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo

An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that sw...

Invitation-only
Schizophrenia
Drug: SEP-363856

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling
Treatment Resistant Depression
Drug: Psilocybin

Trial sponsors

Akili Interactive Labs logo
C
Indivior logo
Karuna Therapeutics logo
Merck Sharp & Dohme (MSD) logo
Otsuka logo
Sumitomo Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems